Terapia con cellule CAR-T in Israele — ricevi 3 opzioni di cliniche personalizzate

Secondo Bookimed, Israele è una destinazione di primo piano per la terapia CAR T-cell grazie ai suoi centri medici di fama mondiale.

• L'Ospedale Ichilov è tra le 10 cliniche più popolari per i turisti medici al mondo, secondo la rivista Newsweek.
• L'Ospedale Ichilov ha un tasso medio di successo del 90% nel trattamento oncologico e tratta oltre 400.000 pazienti ogni anno.
• Il Centro Medico Sheba, un altro ospedale di eccellenza in Israele, conta oltre 1.990 specialità e tratta oltre 1.500.000 pazienti da tutto il mondo ogni anno.

Le recensioni dei pazienti per la terapia CAR T-cell in Israele sono state estremamente positive, con molti che lodano la professionalità e l'approccio orientato al paziente del personale medico.

• Le recensioni menzionano anche l'alto livello di esperienza dei medici, come il Professor Dr. Zvi Ram, il Professor Dr. Feinmesser e il Professor Dr. Amit Ami, che sono alcuni dei chirurghi più rinomati al mondo.
• I coordinatori medici, come Denis Mosher e Victoria, hanno ricevuto grandi elogi per la loro professionalità e per aver offerto relazioni umane calorose e assistenza nell'organizzazione del trattamento.

Israele ha registrato un costante aumento del turismo medico per il trattamento, con pazienti provenienti da una varietà di paesi, inclusi gli Stati Uniti, la Russia e la Germania.

La classifica di Bookimed ha rivelato i primi 5 ospedali in Israele per la terapia CAR T-cell:

1. Centro Schneider per la Medicina dei Bambini
   
2. Centro Medico Hadassah
   
3. Centro Medico Rambam
   
4. Centro Medico Soroka
   
5. Centro Medico Rabin
   

Bookimed ha individuato i migliori medici in Israele specializzati nella terapia CAR T-cell:

1. Ram Ron, Oncoematologia, 21 anni di esperienza
2. Ronit El Hasid, Oncoematologia, 35 anni di esperienza
3. Michael Shapira, Oncoematologia, 33 anni di esperienza, con punteggio recensioni di 5.0
4. Herishanu Yair, Oncoematologia, 21 anni di esperienza
5. Ron Ram, Oncoematologia, 21 anni di esperienza

You do not need a specific CAR T-cell referral to begin. Any hematologist or community oncologist can initiate the process to a specialized center. However, a multidisciplinary team at an accredited Israeli hospital must confirm your final eligibility for treatment.

• Specialist evaluation: Experts like Dr. Ram Ron at Sourasky Medical Center (Ichilov) perform detailed assessments.
• Center accreditation: Major hubs like Sheba Medical Center hold required Ministry of Health certifications.
• Committee approval: National boards and institutional committees must approve cases following strict protocols.
• International access: Patients traveling from abroad can provide medical documentation to start remote reviews.

Bookimed Expert Insight: While any hematologist can refer you, selecting a doctor with a high volume of related procedures speeds up valid documentation. For example, Dr. Ivetta Danylesko at Sheba Medical Center has performed over 3,000 procedures. Working with such experienced specialists helps ensure your medical history meets specific clinical trials or protocol requirements faster.

Patient Consensus: Patients note that pushing a local oncologist to refer directly to a CAR T-cell team can help bypass general queues. Many emphasize that having all previous treatment lines documented is vital for the multi-center board review. It is also common for patients to plan for a three to four month wait even after the initial referral.

Verify Israeli CAR T-cell therapy doctors by confirming their board certification in hematology and oncology through the Scientific Council of the Israel Medical Association. Leading specialists often hold international memberships in the American Society of Hematology and have completed fellowship training at top US institutions.

• Board certification: Qualified specialists hold Israeli board certifications in internal medicine, hematology, and medical oncology.
• Academic contributions: Top experts like Dr. Ron Ram have published over 30 scientific research articles.
• Clinical volume: Leading pediatric specialists like Dr. Ronit El Hasid have performed 300+ successful transplantation procedures.
• International training: Many experts trained at prestigious centers like Stanford University or City of Hope Hospital.

Bookimed Expert Insight: Data shows that premier Israeli specialists often hold significant leadership roles in global organizations. For instance, Dr. Arnon Nagler at Sheba Medical Center served as the Chair for the European Society for Blood and Marrow Transplantation (EBMT) committees. This level of international leadership indicates that these doctors don't just follow protocols but actually help create the global standards for CAR T-cell therapy and transplant medicine.

Patient Consensus: Patients mention that top-tier doctors are very open about sharing their personal results and response rates. They noticed that experienced specialists often have many co-author credits on major clinical trials. Families emphasize that the most skilled pediatric doctors have deep experience in handling complex cases at dedicated children's hospitals.

When choosing a CAR T-cell therapy doctor in Israel, you should look for board-certified hematologists and oncologists with specialized training in cellular immunotherapy. Leading experts often lead bone marrow transplant departments and have extensive experience in treating complex blood cancers like leukemia and lymphoma.

• Hematologic oncology: Seek doctors like Dr. Ron Ram who are board-certified in hematology and oncology.
• Transplantation expertise: Prioritize specialists with deep experience in bone marrow and stem cell transplantation procedures.
• Pediatric specialization: For children, select experts like Dr. Ronit El Hasid who lead pediatric oncohematology departments.
• International training: Top Israeli physicians often complete fellowships at major US institutions like Stanford or SUNY.

Bookimed Expert Insight: Data shows that premier Israeli specialists combine clinical leadership with heavy research involvement. For example, Prof. Arnon Nagler at Sheba Medical Center pioneered reduced-intensity transplant protocols. Choosing a doctor who also serves as a department director ensures they oversee the entire cell processing and recovery cycle at JCI-accredited facilities.

Patient Consensus: Patients often emphasize the importance of finding a doctor familiar with bridging therapies used before the actual cell infusion. They note that feeling supported by a team experienced in managing post-infusion side effects made their recovery much smoother. Many were relieved to work with specialists who have personal experience running clinical trials for the latest cellular products.

Major public medical centers in Israel like Sheba and Sourasky (Ichilov) staff board-certified hematologists with international fellowships in cellular immunotherapy. These facilities operate specialized units for CAR T-cell therapy. Experts here maintain credentials from the American Society of Hematology and other global bodies.

• Specialized units: Sourasky Medical Center houses the Institute for Advanced Cellular Therapies (I-ACT).
• Academic expertise: Prof. Arnon Nagler at Sheba Medical Center completed a postdoctoral fellowship at Stanford.
• Pediatric specialization: Dr. Ronit El Hasid leads pediatric CAR T-cell therapy after training in Los Angeles.
• Multiple certifications: Dr. Ron Ram holds triple board certification in internal medicine, hematology, and oncology.

Bookimed Expert Insight: Data shows that Israeli public centers often feature surgeons who also lead specialized research departments. For example, Dr. Herishanu Yair at Sourasky heads the CLL Department while managing CAR T-cell protocols. This dual role means patients receive care from doctors who directly contribute to the latest clinical protocols and published research.

Patient Consensus: Patients note that doctors at these centers speak English at a level comparable to US specialists. They often mention the long 6-8 month waitlists for public slots but feel the advanced cellular facilities are worth the wait. Many are surprised by how quickly centers like Sheba can manufacture the cells on-site.

Private CAR T-cell therapy consultations with senior Israeli specialists typically range from $500 to $1,350. The public sector offers significantly lower costs for residents through health funds. However, private sessions provide immediate access to department heads and personalized treatment plans without the long wait times.

• Specialist access: Private patients choose specific experts like Dr. Arnon Nagler at Sheba Medical Center.
• Wait times: Private consultations often occur within days compared to months in public systems.
• Clinical credentials: Top doctors hold American Board certifications and memberships in the American Society of Hematology.
• Facility standards: Most senior consultants practice at JCI-accredited hospitals like Sourasky Medical Center (Ichilov).

Bookimed Expert Insight: Data shows that senior specialists in Tel Aviv often maintain dual roles as department heads and private consultants. Dr. Fredi Aviv and Dr. Herishanu Yair bring over 25 years of experience to these sessions. Choosing a private consult at a center like Sourasky allows patients to bypass the standard 6-month public approval queue.

Patient Consensus: Patients note that while public sector co-pays are minimal, the bureaucracy can delay urgent care. Many choose private sessions to get a treatment plan started in days. They describe the experience as worth the cost for the direct time spent with a professor.

Patients should expect a high level of English proficiency from CAR T-cell therapy specialists in Israel. Most leading doctors hold American Board certifications or have completed fellowships at prestigious institutions like Stanford University and SUNY Brooklyn. Hospitals provide dedicated interpretation services for international patients to navigate complex treatment stages.

• International training: Top specialists like Dr. Ron Ram completed fellowships at New York Medical College.
• Global memberships: Many doctors are active members of the American Society of Hematology (ASH).
• Multilingual coordinators: Facilities like Sheba Medical Center provide personal coordinators who manage translation needs.
• Remote interpretation: Simultaneous translation via the Ministry of Health hotline is available during consultations.

Bookimed Expert Insight: Data shows that senior hematologists in Israel often have dual training from both Israeli and North American institutions. For example, Dr. Arnon Nagler at Sheba Medical Center is a Stanford-trained pioneer, while Dr. Ronit El Hasid at Sourasky practiced at City of Hope in Los Angeles. This specific international background means they are comfortable using English as a primary language for medical discussions.

Patient Consensus: Patients find that while lead doctors speak excellent English, some nursing staff may have more limited language skills. Many suggest using a translation app for quick bedside needs but note that hospital coordinators are essential for understanding complex physician instructions.

Israel leads CAR T-cell innovation by running early-phase trials with homegrown constructs for blood cancers and solid tumors. Top experts like Dr. Ron Ram at Sourasky Medical Center (Ichilov) and specialists at Sheba Medical Center develop proprietary vectors. These programs often provide faster access than commercial therapies from the US.

• Academic research leadership: Dr. Ronit El Hasid at Ichilov leads pediatric trials for advanced cellular therapies.
• Proprietary constructs: Hadassah and Bar-Ilan University developed NXC-201 for Multiple Myeloma and AL amyloidosis.
• Fast-track manufacturing: Sheba Medical Center utilizes 10-day on-site manufacturing for next-generation constructs.
• Diverse trial range: Researchers are actively exploring CAR-T applications for lupus and rheumatological diseases.

Bookimed Expert Insight: A unique pattern in Israel is the integration of high-level international training within local research clinics. For example, Dr. Ron Ram and Dr. Arnon Nagler both completed fellowships at Stanford University, while Dr. Ronit El Hasid trained at City of Hope. This global expertise allows Israeli centers to successfully run dual US-Israel clinical trials for complex off-the-shelf and bispecific CAR-T products.

Patient Consensus: Patients note that Israeli doctors often provide access to logic-gated constructs after US programs decline their cases. Relatives say the medical teams quickly manage side effects like cytokine release syndrome during phase 1 trials. Many emphasize having a translator ready because consent forms for early-stage studies are frequently in Hebrew.